Camila Cabello Reveals Why She Stopped Loving Shawn Mendes Shawnmilla fans are still not over the fact that Camila Cabello and Shawn Mendes are no longer together, and theories are still being thrown around about why they really broke up! Did Camila just stop loving Shawn? Did their breakup have anything to do with something […]
The wireless, long-duration, continuous, ultrasound, patch-based stimulator delivers 33 times more treatment than pulsed ultrasound devices and is authorized by the FDA for prescription home use in the United States of…
The Disruptive Intelligent Automation Platform adds Visibility to Security with Multiple Certifications
The OpenBots Team OpenBots attended the B…
Read More
SHANE DAWSON & JEFFREE STAR DOING ANOTHER MAKEUP PALETTE? sponsored by $100 off code Richlux100 JOVS Venus Pro™ II Hair Remover – the best painless hair remover device at home! – Pain-free hair removal experience – Targeted treatment 6 Modes of precise hair removal for different body parts. – Safe and Fast: FDA cleared and […]
Director of the FDA Office of Cosmetics and Colors Speaks to the Association’s Board
WASHINGTON – October 17, 2022 – (Newswire.com)
The Director of the Food and Drug Administration’s (FDA) Office of Cosmetics and Colors Linda Katz, MD, MPH, told members of the Fragrance Creators Association Board of Directors that industry partnerships are key to cosmetic safety.
“The Office of Cosmetics and Colors works to protect public health by overseeing the cosmetics program to help ensure the safety of cosmetic products being sold to consumers. We cannot accomplish this mission alone,” said Dr. Katz. “I want to extend my thanks to Farah and Fragrance Creators’ Board of Directors for the invitation to share my office’s priorities and perspectives. I look forward to advancing our scientific and technical dialogue with the association and its diverse member companies on the safe use of fragrance in finished cosmetics products.”
“Having worked at FDA I understand the importance of establishing trust, building mutual understanding, and exchanging the best available science with industry,” said Fragrance Creators President & CEO Farah K. Ahmed. “We thank Dr. Katz for her strong leadership at FDA’s Office of Cosmetics and Colors and look forward to supporting the Office of Cosmetics and Colors’ goal of assuring the safety of our nation’s cosmetics.”
Leveraging the association’s network of over 1,000 scientist and technical experts, and working with the Research Institute for Fragrance Materials, and allied trades such as the Personal Care Products Council and the Independent Beauty Association, Fragrance Creators continues to educate both the public and government officials about the science and safety of the fragrance value chain as well as the delight and well-being benefits fragrance products deliver every day.
###
Fragrance Creators Association is the trade association representing the majority of fragrance manufacturing in North America. We also represent fragrance-related interests along the value chain. Fragrance Creators’ 60+ member companies are diverse, including large-, medium-, and small-sized companies that create, manufacture, and use fragrances and scents for home care, personal care, home design, fine fragrance, and industrial and institutional products, as well as those that supply fragrance ingredients, including natural extracts and other raw materials that are used in perfumery and fragrance mixtures. Fragrance Creators established and administers the Congressional Fragrance Caucus, ensuring ongoing dialogue with members of Congress and staff. We are an active participant in IFRA and have a designated representative on the IFRA Board to help ensure the associations’ membership is represented in global discussions and the North American perspective is considered in global fragrance positions and policies. Fragrance Creators also produces The Fragrance Conservatory, the comprehensive digital resource for high-quality information about fragrance—www.fragranceconservatory.com. Learn more about Fragrance Creators at fragrancecreators.org—for people, perfume, and the planet.
Contact Information:
Malory Todd
Press Release Service
by
Newswire.com
Original Source:
Fragrance Creators Association Amplifies Ongoing Collaboration and Shared Commitment With the FDA to Advance State-of-the-Art Science
These American Heart Association courses offer a flexible and affordable way to earn CPR, BLS, ACLS, and PALS certification. Safety Training Seminars offers these courses every day of the week – including Saturdays and…
Partnership Extends to all 29 Exer Urgent Care Locations Throughout Southern California
Intend, Inc. intend tm logo
FULLERTON,…
World-ranked powerlifter Robyn Machado praises Stirling’s Delta 8 Sleep gummies and Magnesium Balm for their ability to alleviate pain and soreness from training
CARY, N.C. – October 17, 2022 – (Newswire.com)
After more than 20 years of lifting weights and seven years as a competitive powerlifter, Robyn Machado knows what is needed to stay in top shape, and Stirling CBD’s line of products are her go-to aid for recovery and alleviating pain during training.
Machado, 36, was ranked in the top 10 worldwide in the 60-kilo class. Now competing in the 67.5-kilo class, she was recently ranked 15th in the world. Stirling CBD’s Delta 8 Sleep gummies and Magnesium Balm are key elements of her training. The Delta 8 gummies help Machado stay calm and relaxed without any adverse effects, while the magnesium balm on joints and sore muscles helps alleviate pain and soreness and speed up the healing process.
“When it comes to training, keeping stress to a minimum is optimal, so I use the Magnesium Balm during the day, which helps with inflammation,” said Machado. “But I also train at night, so Delta 8 Sleep Gummies are key in helping me wind down after a workout and to allow me to chill out and get a great night’s sleep. A good night’s sleep is critical to a powerlifter, and Stirling’s gummies help me fall asleep and stay asleep. I wake up feeling refreshed and ready to go.”
Machado regularly sees Dr. Matt Arthur at 919Spine, who recommended the Stirling CBD products and introduced her to Stirling CBD President Joe Kryszak. “I love Stirling’s products. They have really had a positive impact on my training and recovery,” she said. “I’ve tried similar products, but the levels of CBD were too inconsistent. With Stirling, I know I’m getting consistency and the highest-quality product available. They show third party certificates of analysis of each product right on their webpage, so I know exactly what is going into my body.”
CBD Muscle Gel is another lotion that Machado is a big fan of. The Muscle Gel has capsaicin, camphor and menthol, which creates an invigorating cold-hot sensation that helps blood flow in the muscle and joints. In addition, the aloe vera, black pepper extract, and witch hazel ingredients combine for a great solution for pre- and post-workout.
Designed to help alleviate joint pain, Stirling’s CBD lotions are among the most powerful lotions on the market. In addition, all of Stirling’s CBD lotions, gels, and balms are non-GMO-produced, organic, THC-free, vegan, free from additives and chemicals, and are never tested on animals.
For more information, please visit https://www.stirlingcbdoil.com
Contact Information:
Mike Albanese
Related Images
Press Release Service
by
Newswire.com
Original Source:
Stirling CBD Products Help Competitive Powerlifter in Her Training and Recovery
The Optejet® ophthalmic drug device is designed to precisely administer medication to the eye, potentially treating patients’ conditions through gentler, more efficient dosing.
NEW YORK – October 17, 2022 – (Newswire.com)
Two recent studies show that the novel Optejet® dispenser from Eyenovia, Inc., an ophthalmic pharmaceutical technology company, may be a more “human-centric” design than traditional eye droppers, which may make treatments for vision problems, including myopia, presbyopia and mydriasis, easier to deliver.
The investigational Optejet® dispenser administers ophthalmic solutions horizontally using the company’s proprietary Microdose Array Print (MAP™) technology. The system has been shown to deliver accurate microdoses through a precision spray, dispensing medication with the push of a button, with no need to tilt the head back, and requires minimal hand-eye coordination.
Traditional eye drops can deliver four to five times larger volumes of medication than the human eye can hold, which can cause overdosing and drug waste. The Optejet® dispenser is designed to administer 1/5 the volume of solution compared to a traditional eyedropper, making doses less likely to spill or run onto the patient’s face.
“Traditional eye drops typically overdose a patient’s eye with medication and preservatives, which can lead to significant dose-related side effects,” said Michael Rowe, CEO of Eyenovia. “Optejet® is proving to be easier to use and therefore may deliver the appropriate dose of medication to potentially decrease side effects.”
One paper (Rathi, Scott, 2020) presented at the 2020 American Society of Cataract and Refractive Surgery reviewed multiple studies comparing the Optejet® dispenser with traditional eye droppers. In one study with the Optejet®, the researcher successfully administered 96% of doses on the first attempt, and 95% of patients successfully self-administered the doses on the first attempt as well. Another study found ophthalmic technicians successfully delivered doses on 83% of first attempts and were successful 99% of the time within two attempts.
A separate study conducted by Eyenovia (2021) monitored the six-month daily eye drop treatment compliance of 28 children ages 6 to 13 with pediatric progressive myopia. It found that nearly 90% of children using the Optejet® once-daily treatment successfully complied with their treatment regimen. This compares favorably to the 50% compliance rate for pediatric ophthalmic medications or the 59-69% range for adult topical ophthalmic drug users (Naito, 2018; see also Patel, 1995; Winfield, 1990; Matsui, 1997).
The unique delivery mechanism of the Optejet® has the potential to fundamentally change how people think about administering eye medication. Of 100 presbyopic patients between the ages of 40-55, four out of five said they would prefer using the investigational Optejet® device over traditional eye drops, according to a survey conducted by Eyenovia.
Optejet® has not been approved, cleared, or licensed by the U.S. Food and Drug Administration for use, and it is not commercially available in the United States. For more information about the Optejet® device, visit eyenovia.com.
About Eyenovia, Inc.
Eyenovia, Inc. is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAPTM) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis, presbyopia and myopia progression. For more information, visit www.eyenovia.com.
Forward-Looking Statements
Except for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates and platform technology. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment (which could still be adversely impacted by COVID-19), timing, progress and results of such trials; the timing of, and our ability to submit applications for, obtaining and maintaining regulatory approvals for our product candidates; the potential impacts of COVID-19 on our supply chain; the potential advantages of our product candidates and platform technology; the rate and degree of market acceptance and clinical utility of our product candidates; our estimates regarding the potential market opportunity for our product candidates; reliance on third parties to develop and commercialize our product candidates; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our product candidates; intellectual property risks; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and our competitive position. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws. Eyenovia does not undertake any obligation to update any forward-looking statements.
Contact Information:
Norbert Lowe
Vice President, Commercial Operations
Buse Kayar
Press Release Service
by
Newswire.com
Original Source:
Investigational Optejet® Microdose Dispenser from Eyenovia Shows Promise in Improving Treatment for Myopia, Presbyopia and Patients Getting Eye Exams
Digital Front Door platform welcomes new advisor to advisory board
ST. PETERSBURG, Fla. – October …
Read More